Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 36, Issue 5, 1997, Pages 685-693

  McDougle, Christopher J ^a,b   Holmes, Janice P ^c   Bronson, Mary R ^c   Anderson, George M ^c   Volkmar, Fred R ^c   Price, Lawrence H ^c   Cohen, Donald J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yale Medical Group   (United States)

^c NONE

Author keywords

aggression; autistic disorder; mental retardation; repetitive behavior; risperidone

Indexed keywords

PLACEBO; RISPERIDONE;

ADOLESCENT; ARTICLE; ASPERGER SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; INFANTILE AUTISM; MALE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; SCHIZOPHRENIA; SCHOOL CHILD; STATISTICAL ANALYSIS; TREATMENT PLANNING;

EID: 0030937715     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004583-199705000-00020     Document Type: Article

References (42)

1. American Psychiatric Association (1994), Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington, DC: American Psychiatric Association
2. Buzan RD (1996), Risperidone-induced tardive dyskinesia (letter). Am J Psychiatry 153:734-735
3. Campbell M, Adams P, Perry R, Spencer EK, Overall JE (1988), Tardive and withdrawal dyskinesia in autistic children: a prospective study. Psychopharmacol Bull 24:251-255
4. Campbell M, Anderson LT, Meier M et al. (1978), A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 17:640-655
5. Casaer P, Walleghem D, Vandenbussche I, Huang M-L, De Smedt G (1994), Pharmacokinetics and safety of risperidone in autistic children. Pediatr Neurol 11:89
6. Chouinard G, Jones B, Remington G et al. (1993), A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25-40
7. Corbett R, Hartman H, Kerman LL et al. (1993), Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol Biochem Behav 45:9-17
8. Cozza SJ, Edison DL (1994), Risperidone in adolescents (letter). J Am Acad Child Adolesc Psychiatry 33:1211
9. Daniel DG, Smith K, Hyde T, Egan M (1996), Neuroleptic-induced tardive dyskinesia (letter). Am J Psychiatry 153:734
10. Demb H (1995), Risperidone: maybe this shouldn't be the last resort. In: Success Stories in Developmental Disabilities, Vol IV, Antanitus D, ed. Waltham, MA: Liberty Healthcare Corporation, pp 11-14
11. Demb HB (1996), Risperidone in young children with pervasive developmental disorders and other developmental disabilities (letter). J Child Adolesc Psychopharmacol 6:79-80
12. Edleman RJ (1996), Risperidone side effects (letter). J Am Acad Child Adolesc Psychiatry 35:4-5
13. Fras I, Major LF (1995), Clinical experience with risperidone (letter). J Am Acad Child Adolesc Psychiatry 34:833
14. Freeman BJ, Ritvo ER, Yokota A, Ritvo A (1986), A scale for rating symptoms of patients with the syndrome of autism in real life settings. J Am Acad Child Psychiatry 25:130-136
15. Goodman WK, Price LH, Rasmussen SA et al. (1989a), The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): I. Development, use, and reliability. Arch Gen Psychiatry 46:1006-1011
16. Goodman WK, Price LH, Rasmussen SA et al. (1989b), The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): II. Validity. Arch Gen Psychiatry 46:1012-1016
17. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL (1993), A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 50:441-447
18. Guy W (1976), ECDEU Assessment Manual for Psychopharmacology (Publication 76-338). Washington, DC: US Department of Health, Education, and Welfare
19. Le Couteur A, Rutter M, Lord C et al. (1989), Autism Diagnostic Interview: a standardized investigator-based instrument. J Autism Dev Disord 19:363-387
20. Leiter RG (1948), Leiter International Performance Scale. Chicago: Stoelting Co
21. Leysen JE, Gommeren W, Eens A, De Chaffoy De Courcelles D, Stoof JC, Janssen PAJ (1988), Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247:661-670
22. Lombroso PJ, Scahill L, King RA et al. (1995), Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry 34:1147-1152
23. Lord C, Rutter M, Goode S et al. (1989), Autism Diagnostic Observation Schedule: a standardized observation of communicative and social behavior. J Autism Dev Disord 19:185-212
24. Mandoki MW (1995), Risperidone treatment of children and adolescents: Increased risk of extrapyramidal side effects? J Child Adolesc Psychopharmacol 5:49-67
25. McDougle CJ, Brodkin ES, Yeung PP, Naylor ST, Cohen DJ, Price LH (1995a), Risperidone in adults with autism or pervasive developmental disorder. J Child Adolesc Psychopharmacol 5:273-282
26. McDougle CJ, Fleischmann RL, Epperson CN, Wasylink S, Leckman JF, Price LH (1995b), Risperidone addition in fluvoxamine-refractory obsessive compulsive disorder: three cases. J Clin Psychiatry 56:526-528
27. McDougle CJ, Kresch LE, Goodman WK et al. (1995c), A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry 152:772-777
28. McDougle CJ, Naylor ST, Goodman WK, Volkmar FR, Cohen DJ, Price LH (1993), Acute tryptophan depletion in autistic disorder: a controlled case study. Biol Psychiatry 33:547-550
29. Mollet HJ, Pelzer E, Kissling W, Riehl T, Wernicke T (1991), Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study. Pharmacopsychiatry 24:185-189
30. Naruse H, Nagahata M, Nakane Y, Shirahashi K, Takesada M, Yamazaki K (1982), A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavior disorders, using cross-over design. Acta Paedopsychiatr 48:173-184
31. Perry RI, Pataki CS, Munoz DM, Armenteros JL, Silva RR (1996), Pilot trial of risperidone in children and adolescents with pervasive developmental disorder. In: Proceedings of the 149th Annual Meeting of the American Psychiatric Association, New York, New Research Abstract 226, p 129
32. Purdon SE, Lit W, Labelle A, Jones BD (1994), Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry 39:400-405
33. Quintana H, Keshavan M (1995), Case study: risperidone in children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 34:1292-1296
34. Riddle MA, Geller B, Ryan N (1993), Another sudden death in a child treated with desipramine. J Am Acad Child Adolesc Psychiatry 32:792-797
35. Schuster CR, Lewis M, Seiden LS (1986), Fenfluramine: neurotoxicity. Psychopharmacol Bull 22:148-151
36. Simeon JG, Carrey NJ, Wiggins DM, Milin RP, Hosendocus SN (1995), Risperidone effects in treatment-resistant adolescents: preliminary case reports. J Child Adolesc Psychopharmacol 5:69-79
37. Sparrow SS, Balla DA, Cicchetti DV (1984), Vineland Adaptive Behavior Scales (A Revision of the Vineland Social Maturity Scale by Edgar A. Doll). Circle Pines, MN: American Guidance Service
38. Sternlicht HC, Wells SR (1995), Risperidone in childhood schizophrenia (letter). J Am Acad Child Adolesc Psychiatry 34:540
39. Vanden Borre R, Vermote R, Buttiens M et al. (1993), Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study. Acta Psychiatr Scand 87:167-171
40. Wechsler D (1992), Manual for the Wechsler Intelligence Scale for Children, 3rd ed. San Antonio, TX: Psychological Corporation
41. Woerner MG, Sheitman BB, Lieberman JA, Kane JM (1996), Tardive dyskinesia induced by risperidone? (letter). Am J Psychiatry 153:843
42. World Health Organization (1990), International Classification of Diseases, 10th ed. Geneva: World Health Organization